Understanding how ADAM9 affects eye health and disease
The role of ADAM9 in retinal health and disease
This study is looking at a protein called ADAM9 to understand how it affects eye health and could help find new treatments for vision loss, especially for people dealing with retinal diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11142677 on NIH RePORTER |
What this research studies
This research investigates the role of a specific protein, ADAM9, in the health of the retina and its involvement in diseases that cause vision loss. By studying genetically modified mouse models, researchers aim to uncover how mutations in ADAM9 lead to degeneration of photoreceptors, which are crucial for vision. The project will utilize advanced techniques to analyze the interactions between photoreceptors and the retinal pigment epithelium, potentially revealing new insights into retinal diseases. Patients may benefit from findings that could lead to new treatments for conditions like blindness caused by retinal degeneration.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals with genetic mutations affecting ADAM9 and those experiencing retinal degeneration.
Not a fit: Patients with retinal diseases not related to ADAM9 mutations may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for preventing or treating retinal diseases that cause blindness.
How similar studies have performed: Previous research in animal models has shown promising results in understanding the role of ADAM proteins in retinal health, suggesting that this approach may yield valuable insights.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Lewis, Tylor Robert — University of Alabama at Birmingham
- Study coordinator: Lewis, Tylor Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.